Frequent Loss of CHD1 in the Prostate Cancer of African Americans and Its Potential Role in Increased Sensitivity to Platinum or PARP Inhibitor-Based Therapy
Technical Report,30 Sep 2018,29 Sep 2019
Childrens Hospital Boston United States
Pagination or Media Count:
African American individuals with prostate cancer have significantly worse clinical outcome than European Americans with the same disease. In our preliminary analysis, we identified a specific molecular aberration that is present in African American prostate cancer cases two to three times more frequently than in European Americans with the same disease. This aberration, the loss of the CHD1 gene, is thought to lead to impaired homologous recombination and increased genomic instability. Homologous recombination HR deficiency can be therapeutically exploited by either platinum or PARP inhibitor-based therapy. Therefore, we are performing a comprehensive analysis of the clinical consequences of the increased prevalence of CHD1 loss in the prostate cancer of African American individuals. We are investigating the relationship between CHD1 loss and the HRD mutational signatures. A robust association between CHD1 loss and HR deficiency may be the mechanistic basis for effective, platinum or PARP inhibitor-based personalized therapy for African American prostate cancer cases.
- Medicine and Medical Research